Cargando…

A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers

OBJECTIVE: To evaluate the combination of ultrasonic debridement and cortex phellodendri compound fluid (CPCF) in patients with diabetic foot ulcers (DFU). PATIENTS AND METHODS: Patients with DFU received the combination of ultrasonic debridement and CPCF in the experimental group and Kangfuxin liqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hang, Chen, Jiali, Zhao, Ziying, Wang, Guangyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371514/
https://www.ncbi.nlm.nih.gov/pubmed/35960115
http://dx.doi.org/10.1097/MD.0000000000029604
_version_ 1784767163937062912
author Gao, Hang
Chen, Jiali
Zhao, Ziying
Wang, Guangyi
author_facet Gao, Hang
Chen, Jiali
Zhao, Ziying
Wang, Guangyi
author_sort Gao, Hang
collection PubMed
description OBJECTIVE: To evaluate the combination of ultrasonic debridement and cortex phellodendri compound fluid (CPCF) in patients with diabetic foot ulcers (DFU). PATIENTS AND METHODS: Patients with DFU received the combination of ultrasonic debridement and CPCF in the experimental group and Kangfuxin liquid in the control group for 4 weeks. Patients total clinical efficiency, adverse events, ulcer areas, healing rate, and positive bacterial culture rate were compared. RESULTS: The total clinical efficacy was 98% in the treatment group and 68% in the control group (P < .0001). Patients’ adverse events did not show significant difference between 2 groups. Patients who received the combination of ultrasonic debridement and CPCF in the experimental group had smaller ulcer areas (2.88 ± 0.2408 vs 6.912 ± 0.4044), higher healing rate (96.25 ± 0.5263 vs 55 ± 0.8888), and lower positive bacterial culture rate (0 vs 20%) than patients received Kangfuxin liquid in the control group after 4 weeks of treatment. CONCLUSIONS: In conclusion, patients with DFU receiving the combination of ultrasonic debridement and CPCF had better clinical efficacy, smaller ulcer areas, higher healing rate, and lower positive bacterial culture rate without increasing the adverse events compared to patients receiving Kangfuxin liquid.
format Online
Article
Text
id pubmed-9371514
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93715142022-08-16 A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers Gao, Hang Chen, Jiali Zhao, Ziying Wang, Guangyi Medicine (Baltimore) Research Article OBJECTIVE: To evaluate the combination of ultrasonic debridement and cortex phellodendri compound fluid (CPCF) in patients with diabetic foot ulcers (DFU). PATIENTS AND METHODS: Patients with DFU received the combination of ultrasonic debridement and CPCF in the experimental group and Kangfuxin liquid in the control group for 4 weeks. Patients total clinical efficiency, adverse events, ulcer areas, healing rate, and positive bacterial culture rate were compared. RESULTS: The total clinical efficacy was 98% in the treatment group and 68% in the control group (P < .0001). Patients’ adverse events did not show significant difference between 2 groups. Patients who received the combination of ultrasonic debridement and CPCF in the experimental group had smaller ulcer areas (2.88 ± 0.2408 vs 6.912 ± 0.4044), higher healing rate (96.25 ± 0.5263 vs 55 ± 0.8888), and lower positive bacterial culture rate (0 vs 20%) than patients received Kangfuxin liquid in the control group after 4 weeks of treatment. CONCLUSIONS: In conclusion, patients with DFU receiving the combination of ultrasonic debridement and CPCF had better clinical efficacy, smaller ulcer areas, higher healing rate, and lower positive bacterial culture rate without increasing the adverse events compared to patients receiving Kangfuxin liquid. Lippincott Williams & Wilkins 2022-08-12 /pmc/articles/PMC9371514/ /pubmed/35960115 http://dx.doi.org/10.1097/MD.0000000000029604 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gao, Hang
Chen, Jiali
Zhao, Ziying
Wang, Guangyi
A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers
title A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers
title_full A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers
title_fullStr A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers
title_full_unstemmed A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers
title_short A combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers
title_sort combination of ultrasonic debridement and topical cortex phellodendri compound fluid in patients with diabetic foot ulcers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371514/
https://www.ncbi.nlm.nih.gov/pubmed/35960115
http://dx.doi.org/10.1097/MD.0000000000029604
work_keys_str_mv AT gaohang acombinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers
AT chenjiali acombinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers
AT zhaoziying acombinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers
AT wangguangyi acombinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers
AT gaohang combinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers
AT chenjiali combinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers
AT zhaoziying combinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers
AT wangguangyi combinationofultrasonicdebridementandtopicalcortexphellodendricompoundfluidinpatientswithdiabeticfootulcers